m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00033)
Target Name hsa-miR-186-5p
Synonyms
hsa_miR_186_5p
    Click to Show/Hide
Gene Name hsa-miR-186-5p
miRBase ID
MIMAT0000456
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
hsa-miR-186-5p can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary Platinum can increase the overall m6A level of esophageal cancer. SNHG3/hsa-miR-186-5p, induced by platinum, was involved in regulating m6A level by targeting METTL3. miR-186-5p binds to the 3'UTR of METTL3 to inhibit its expression. Our manuscript has provided clues that regulating m6A level was a novel way to enhance the platinum efficacy.
Target Regulation Up regulation
Responsed Disease Esophageal cancer ICD-11: 2B70
 Disease Info 
Responsed Drug Pt Investigative
 Drug Info 
Cell Process Cellular Processes
Cell growth and death
Cell apoptosis
In-vitro Model Eca-9706 (Esophageal carcinoma cell line)
KYSE-150 Esophageal squamous cell carcinoma Homo sapiens CVCL_1348
In-vivo Model Used 1 × 106 SNHG3 knocked down KY-SE150 cells and NC lentivirus to inject into the right flank of mice to generate xenografts.
Esophageal cancer [ICD-11: 2B70]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary Platinum can increase the overall m6A level of esophageal cancer. SNHG3/hsa-miR-186-5p, induced by platinum, was involved in regulating m6A level by targeting METTL3. miR-186-5p binds to the 3'UTR of METTL3 to inhibit its expression. Our manuscript has provided clues that regulating m6A level was a novel way to enhance the platinum efficacy.
Responsed Disease Esophageal cancer [ICD-11: 2B70]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Drug Pt Investigative
 Drug Info 
Cell Process Cellular Processes
Cell growth and death
Cell apoptosis
In-vitro Model Eca-9706 (Esophageal carcinoma cell line)
KYSE-150 Esophageal squamous cell carcinoma Homo sapiens CVCL_1348
In-vivo Model Used 1 × 106 SNHG3 knocked down KY-SE150 cells and NC lentivirus to inject into the right flank of mice to generate xenografts.
Pt [Investigative]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary Platinum can increase the overall m6A level of esophageal cancer. SNHG3/hsa-miR-186-5p, induced by platinum, was involved in regulating m6A level by targeting METTL3. miR-186-5p binds to the 3'UTR of METTL3 to inhibit its expression. Our manuscript has provided clues that regulating m6A level was a novel way to enhance the platinum efficacy.
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Disease Esophageal cancer ICD-11: 2B70
 Disease Info 
Cell Process Cellular Processes
Cell growth and death
Cell apoptosis
In-vitro Model Eca-9706 (Esophageal carcinoma cell line)
KYSE-150 Esophageal squamous cell carcinoma Homo sapiens CVCL_1348
In-vivo Model Used 1 × 106 SNHG3 knocked down KY-SE150 cells and NC lentivirus to inject into the right flank of mice to generate xenografts.
References
Ref 1 Targeting SNHG3/miR-186-5p reverses the increased m6A level caused by platinum treatment through regulating METTL3 in esophageal cancer. Cancer Cell Int. 2021 Feb 17;21(1):114. doi: 10.1186/s12935-021-01747-9.